NNI-351

NNI-351
Clinical data
Routes of; administration	By mouth
Identifiers
	IUPAC name 4-(3-Cyano-6-ethoxyquinolin-2-yl)-N-(2-fluorophenyl)-1,4-diazepane-1-carbothioamide;
CAS Number	929607-23-8 ;
PubChem CID	16661882;
ChemSpider	17594951;
UNII	97LG4X5P2E;
Chemical and physical data
Formula	C24H24FN5OS
Molar mass	449.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCOC1=CC2=C(C=C1)N=C(C(=C2)C#N)N3CCCN(CC3)C(=S)NC4=CC=CC=C4F;
	InChI InChI=1S/C24H24FN5OS/c1-2-31-19-8-9-21-17(15-19)14-18(16-26)23(27-21)29-10-5-11-30(13-12-29)24(32)28-22-7-4-3-6-20(22)25/h3-4,6-9,14-15H,2,5,10-13H2,1H3,(H,28,32); Key:RQXUPDSAFGWKMO-UHFFFAOYSA-N;

NNI-351 is an orally active inhibitor of DYRK1ATooltip dual specificity tyrosine-phosphorylation-regulated kinase 1A and neurogenesis enhancer which is under development by NeuroNascent, Inc. for the treatment of Down syndrome, depression, and post-traumatic stress disorder (PTSD).^[1]^[2] As of 2017, it is in the preclinical development stage, and has yet to progress to human clinical trials.^[1] In July 2022, NNI-351 was granted orphan drug status by the FDA for the treatment of Fragile X syndrome.^[3]

References

^ ^a ^b "Research programme: Psychiatric and neurological disorders therapeutics - Neuronascent - AdisInsight".
^ Froestl W, Muhs A, Pfeifer A (2013). "Cognitive enhancers (nootropics). Part 2: drugs interacting with enzymes". J. Alzheimer's Dis. 33 (3): 547–658. doi:10.3233/JAD-2012-121537. PMID 23042218. S2CID 34896894.
^ "Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome". GlobeNewswire News Room. GlobalNewsWire. 1 June 2022. Retrieved 15 January 2023.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.